Assembly Biosciences (NASDAQ:ASMB) Stock Rating Upgraded by Wall Street Zen

Assembly Biosciences (NASDAQ:ASMB) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday.

A number of other brokerages have also recently issued reports on ASMB. HC Wainwright reissued a “buy” rating and set a $50.00 price objective on shares of Assembly Biosciences in a report on Monday, December 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Assembly Biosciences in a report on Wednesday, January 21st. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Assembly Biosciences presently has an average rating of “Moderate Buy” and an average target price of $41.75.

Assembly Biosciences Price Performance

Shares of ASMB stock opened at $28.46 on Friday. The stock has a market capitalization of $450.24 million, a price-to-earnings ratio of -38.46 and a beta of 1.11. The company’s fifty day simple moving average is $28.16 and its two-hundred day simple moving average is $29.58. Assembly Biosciences has a 1 year low of $7.75 and a 1 year high of $39.71.

Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings results on Thursday, March 19th. The biopharmaceutical company reported $2.48 EPS for the quarter, topping analysts’ consensus estimates of ($0.51) by $2.99. The firm had revenue of $42.47 million during the quarter, compared to analyst estimates of $7.42 million. Assembly Biosciences had a negative return on equity of 8.06% and a negative net margin of 8.47%. Equities research analysts anticipate that Assembly Biosciences will post -6.87 EPS for the current year.

Institutional Investors Weigh In On Assembly Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in ASMB. Bank of America Corp DE boosted its stake in Assembly Biosciences by 6,382.7% during the third quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock valued at $86,000 after buying an additional 3,319 shares during the period. Seven Fleet Capital Management LP bought a new position in Assembly Biosciences in the 4th quarter worth about $147,000. Acadian Asset Management LLC increased its stake in Assembly Biosciences by 42.1% in the 1st quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock worth $219,000 after acquiring an additional 6,823 shares during the last quarter. Charles Schwab Investment Management Inc. purchased a new stake in shares of Assembly Biosciences in the 4th quarter valued at about $228,000. Finally, Virtus Investment Advisers LLC purchased a new stake in shares of Assembly Biosciences in the 4th quarter valued at about $251,000. Hedge funds and other institutional investors own 19.92% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.